FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

By Alexandra Pecci • Aug. 17, 2026

BioNTech’s oncology pivot comes with a new CEO

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

By Kelly Bilodeau • Aug. 14, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Biotech initiatives pick up as more regions race to become hubs

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

By Alexandra Pecci • Aug. 13, 2026

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

By Alexandra Pecci • Aug. 12, 2026

Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?

While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.

By Kelly Bilodeau • Aug. 10, 2026

FDA allows unique endpoint in rare disease study

Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.

By Alexandra Pecci • Aug. 5, 2026

Three potential takeover targets in psychedelics

Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.

By Kelly Bilodeau • Aug. 4, 2026

Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision

Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.

By PharmaVoice Staff • July 31, 2026

How Telix landed a $2.1 billion radiopharma deal with Regeneron

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement. 

By Alexandra Pecci • July 30, 2026

BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.

Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.

By Kelly Bilodeau • July 29, 2026

Why 3 secretive biotechs are keeping their science close to the chest

Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.

By Kelly Bilodeau • July 27, 2026

Lilly’s leap into psychedelics; peptides in the spotlight

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs. 

By PharmaVoice Staff • July 24, 2026

Biopharma challenges leaders want to tackle

Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.

By Meagan Parrish • July 23, 2026

As the Ebola outbreak rages, new treatments are headed into trials. Will they work?

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

By Alexandra Pecci • July 20, 2026

Long days, dinners with copious alcohol, and the hunt for emerging assets in China

Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.

By Meagan Parrish • July 17, 2026

This startup thinks humans in clinical trials could become a ‘formality’

Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.

By Alexandra Pecci • July 16, 2026

Galimedix is keeping the amyloid hypothesis alive

The right target but the wrong approach? Why Galimedix’s co-founder believes the company has found an edge in treating Alzheimer’s disease with an amyloid drug.

By Kelly Bilodeau • July 14, 2026

Biotech funding gap widens despite rebound in VC investment

Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.

By Gwendolyn Wu • July 14, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

By Alexandra Pecci • June 29, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in offerings later this year — but only among companies fitting a certain criteria.  

By Gwendolyn Wu • June 23, 2026